Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 92 | ETA2023 | Next issue

45th Annual Meeting of the European Thyroid Association (ETA) 2023

Poster Presentations

Treatment 1

ea0092ps2-18-01 | Treatment 1 | ETA2023

Role of radiofrequency ablation in the treatment of symptomatic distant metastasis of thyroid cancer

Chung Sae Rom , Hwan Baek Jung , Jun Choi Young , Sung Tae-Yon , Eun Song Dong , Yong Kim Tae , Hyun Lee Jeong

Objective: To evaluate the effectiveness and safety of ultrasound-guided RFA for symptomatic distant metastasis of DTC.Methods: The medical records of 12 patients who underwent RFA for palliative treatment of 18 symptomatic distant metastases from thyroid cancer between January 2008 and December 2020 were analyzed. All patients were assessed for their degree of discomfort, and were evaluated periodically as outpatients, clinically, and by imaging and ser...

ea0092ps2-18-02 | Treatment 1 | ETA2023

Abstract withdrawn...

ea0092ps2-18-03 | Treatment 1 | ETA2023

A systematic drug repurposing approach for anaplastic thyroid cancer

Manzotti Gloria , Torricelli Federica , Manicardi Veronica , Faria do Valle Italo , Piana Simonetta , Ciarrocchi Alessia

Anaplastic thyroid cancer (ATC) is the most aggressive and lethal form of thyroid cancer. ATC rarely develop as ex-novo lesions, but rather evolves from pre-existing well-differentiated thyroid cancer (DTC) through a de-differentiation process that leads cells to acquire an aggressive phenotype. ATC are refractory to radiotherapy, having lost the expression of Sodium-Iodine Symporter, and often also to standard chemotherapy. Moreover, debulking surgery is frequently difficult,...

ea0092ps2-18-04 | Treatment 1 | ETA2023

Comparative effectiveness of selpercatinib vs standard treatment in patients with medullary thyroid cancer: An interpatient analysis from libretto-001

Wirth Lori , Worden Francis , Morris John , Medioni Jacques , Deschler-Baier Barbara , Han Yimei , Kiiskinen Urpo , Jen Min-Hua , Barker Scott , Szymczak Sylwia , Gilligan Adrienne

Objective: Head-to-head data comparing selpercatinib, a highly selective and potent RE arranged during Transfection (RET) kinase inhibitor with CNS activity, to standard treatment of RET-altered medullary thyroid cancer (MTC; cabozantinib or vandetanib) is currently unavailable. This post-hoc comparative effectiveness analysis of data from the phase 1/2 LIBRETTO-001 trial compared investigator-assessed outcomes among patients with RET</e...

ea0092ps2-18-05 | Treatment 1 | ETA2023

The first experience of laser interstitial thermotherapy in the treatment of patients with nodular goiter and cytology tbsrtc iv

Palamarchuk Volodymyr , Tovkai Oleksandr , Kozachuk Yelyzaveta , Zemskov Sergii , Belemets Nataliia , Stotska Lyudmyla

The objective was to evaluate the short-term results of the laser interstitial thermotherapy (LITT) application in the treatment of patients with nodular goiter and cytology TBSRTC IV category.Materials and methods: In 2021-2023, ultrasound-guided LITT was performed on 21 patients with nodular goiter and cytology TBSRTC IV. Laser type - GaAlAs Diode Laser (VELAS II-30F). The wavelength was 1064 nm, and the emission mode - continuous. Power at the 1st ses...

ea0092ps2-18-06 | Treatment 1 | ETA2023

Prognostic model of the rate and risk of papillary thyroid cancer local metastases based on preoperative clinical and ulrasonic predictors

Lishchynskyi Pavlo , Tovkai Oleksandr , Palamarchuk Volodymyr , Zemskov Sergii , Kuts Volodymyr

Introduction: Papillary thyroid cancer (PTC) is an indolent tumor with low malignancy potential. However, occult synchronous cervical lymph node metastases (CLNM), which may lead to a high risk of local recurrence, are still present in 20–40% of patients. The low diagnostic efficiency (< 47%) of the neck ultrasound in central lymph node metastases detection leads to the development of alternative ways of occult CLNM prediction in patients with PTC. The objective is to...

ea0092ps2-18-07 | Treatment 1 | ETA2023

Role of preoperative serum calcitonin and carcinoembryonic antigen in predicting surgical extent of lateral lymph node metastasis in medullary thyroid carcinoma: a multicenter study in korea

Kim Bohyun , Kim Mijin , Gu Kim Won , Jun Lim Dong , Kyung Kim Hee , Kang Ho-Cheol , Ahn Byeong-Cheol , Sook Kim Eun , Bae Kim Won , Kee Shong Young

Background: The optimal initial surgical extent for medullary thyroid carcinoma (MTC) remains controversial. Aim of this study was to evaluate the ability of serum calcitonin and carcinoembryonic antigen(CEA) to predict the extent of surgery needed in the lateral neck in patients with MTC.Methods: This retrospective multicenter cohort study included data from patients with MTC surgically treated in the 6 tertiary medical centers in Korea from 1996 to 202...

ea0092ps2-18-08 | Treatment 1 | ETA2023

Clinical practice guidelines for radiofrequency ablation of benign thyroid nodules and malignant thyroid cancers: A systematic review

Kyoung Lee Min , Hwan Baek Jung , Lyung Jung So , Gyu Na Dong

Objectives: Radiofrequency ablation (RFA) is considered an alternative treatment for benign thyroid nodules and malignant thyroid cancers. There were various clinical practice guidelines from international societies for ablation of benign thyroid nodules. Recently, RFA is becoming a promising treatment choice for recurrence thyroid cancer, and RFA is suggested as a minimally invasive treatment for low-risk papillary thyroid microcarcinoma (PTMC). Several international societie...

ea0092ps2-18-09 | Treatment 1 | ETA2023

Evaluation of real-world efficacy in lenvatinib and pembrolizumab treated poorly (PDTC) and anaplastic (ATC) thyroid cancer patients

Brandenburg Tim , Maria Machlah Yara , Theurer Sarah , Dralle Henning , Weber Manuel , Weber Frank , Lahner Harald , Fuhrer Dagmar

Anaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy with only limited effective systemic treatment options. The identification of actionable genetic lesions and its exploitation has expanded therapeutic approaches and especially for the subset of BRAFV600E mutated ATC (11-25%) combined BRAF- and MEK-inhibition indicated meaningful activity. Still, further effective therapeutic options are required for patients without identifiable driver mutations. The role ...